Display options
Cite
Turshudzhyan A, Hadfield M, Grant-Kels J. Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma. Melanoma Res. 2021;31(5):421-425doi: 10.1097/CMR.0000000000000766.
Turshudzhyan, A., Hadfield, M., & Grant-Kels, J. (2021). Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma. Melanoma research, 31(5), 421-425. https://doi.org/10.1097/CMR.0000000000000766
Turshudzhyan, Alla, et al. "Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma." Melanoma research vol. 31,5 (2021): 421-425. doi: https://doi.org/10.1097/CMR.0000000000000766
Turshudzhyan A, Hadfield M, Grant-Kels J. Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma. Melanoma Res. 2021 Oct 01;31(5):421-425. doi: 10.1097/CMR.0000000000000766. PMID: 34284460.
Copy Download .nbib Format: NLM
Share it on

Melanoma Res. 2021 Oct 01;31(5):421-425. doi: 10.1097/CMR.0000000000000766.

Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma.

Melanoma research

Alla Turshudzhyan, Matthew Hadfield, Jane Grant-Kels

Affiliations

  1. Department of Internal Medicine and Dermatology, University of Connecticut, Farmington, Connecticut, USA.

PMID: 34284460 DOI: 10.1097/CMR.0000000000000766

Abstract

Merkel-cell carcinoma (MCC) is a rare and extremely aggressive nonmelanocytic cutaneous neuroendocrine carcinoma. Historically, it has been associated with limited therapy options and poor prognosis. While its incidence has been rising over the last two decades, recent discoveries and a better understanding of its pathogenesis, viral association and immunologic features have allowed for the emergence of new therapies. Surgical excision with or without radiotherapy remains the first-line therapy for primary lesions without evidence of metastatic disease. The majority of MCC cases are regrettably diagnosed at advanced stages and oftentimes require systemic therapy. There have been several significant advances in the treatment of MCC in the last decade. Among these have been the development of immune checkpoint inhibitors targeting the programmed death protein-1 (PD-1)/programmed death ligand-1 (PDL-1). Despite recent success of immunotherapy, nearly 50% of patients diagnosed with MCC still succumb to the disease. Fortunately, there has been a number of new targeted therapies that hold great promise. Among them are phosphatidylinositide-3kinase (Pl3K) inhibitors, adoptive T-cell immunotherapy, activated NK-92 cells infusions and therapeutic vaccines. Additional emerging therapeutic targets include cellular ubiquitin-specific processing protease 7 (Usp7) that restricts viral replication and IFN genes (STING), activation of which promotes an antitumor inflammatory response.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

References

  1. Moll I. Merkelzellkarzinom [Merkel-cell carcinoma]. Pathologe 2019; 40(Suppl 3):350–354. - PubMed
  2. Cardoso JC, Teixeira V, Tchernev G, Wollina U. Merkel cell carcinoma: a review and update on aetiopathogenesis, diagnosis and treatment approaches. Wien Med Wochenschr 2013; 163:359–367. - PubMed
  3. Paulson KG, Park SY, Vandeven NA, Lachance K, Thomas H, Chapuis AG, et al. Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol 2018; 78:457–463.e2. - PubMed
  4. Robinson CG, Tan D, Yu SS. Recent advances in Merkel cell carcinoma. F1000Res 2019; 8:F1000 Faculty Rev-1995. - PubMed
  5. Jiang P, Lai J. Merkel cell carcinoma clinically mimicking a traumatic suture scar in the nasal vestibule: earlier diagnosis for better prognosis. Anticancer Res 2020; 40:1123–1126. - PubMed
  6. Brummer GC, Bowen AR, Bowen GM. Merkel cell carcinoma: current issues regarding diagnosis, management, and emerging treatment strategies. Am J Clin Dermatol 2016; 17:49–62. - PubMed
  7. Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev 1999; 8:153–158. - PubMed
  8. Czech-Sioli M, Günther T, Therre M, Spohn M, Indenbirken D, Theiss J, et al. High-resolution analysis of Merkel Cell Polyomavirus in Merkel Cell Carcinoma reveals distinct integration patterns and suggests NHEJ and MMBIR as underlying mechanisms. Plos Pathog 2020; 16:e1008562. - PubMed
  9. Mendoza MD, Santonja C, Gonzalez-Vela C, Concha A, Iglesias Pena N, Andrés-Esteban EM, et al. The presence of Merkel cell carcinoma polyomavirus is associated with a distinct phenotype in neoplastic Merkel cell carcinoma cells and their tissue microenvironment. PLoS One 2020; 15:e0232517. - PubMed
  10. Steven N, Lawton P, Poulsen M. Merkel cell carcinoma - current controversies and future directions. Clin Oncol (R Coll Radiol) 2019; 31:789–796. - PubMed
  11. Abbasi AN, Ahmed SM, Qureshi BM. Recent updates in the management of Merkel Cell Carcinoma. J Pak Med Assoc 2019; 69:1693–1699. - PubMed
  12. Cornejo C, Miller CJ. Merkel cell carcinoma: updates on staging and management. Dermatol Clin 2019; 37:269–277. - PubMed
  13. Sadeghinia A, Ghanadan A, Ehsani A, Noormohammadpour P, Ansari MS. Can dermoscopy open a new way to diagnosing Merkel cell carcinoma? Int J Dermatol 2019; 58:e68–e71. - PubMed
  14. Nguyen BD. Positron emission tomographic imaging of Merkel cell carcinoma. Clin Nucl Med 2002; 27:922–923. - PubMed
  15. Lu Y, Fleming SE, Fields RC, Coit DG, Carrasquillo JA. Comparison of 18F-FDG PET/CT and 111In-pentetreotide scan for detection of Merkel cell carcinoma. Clin Nucl Med. 2012; 37:759–762. - PubMed
  16. García-Harana C, Fernandez-Canedo I, Rodriguez-Lobalzo S, de Troya-Martín M. Merkel Cell Carcinoma: is there a distinctive ultrasound pattern? Carcinoma de células de Merkel: ¿existe un patrón ecográfico distintivo? Actas Dermosifiliogr. 2019; 110:503–506. - PubMed
  17. Leblebici C, Yeni B, Savli TC, Aydin Ö, Güneş P, Cinel L, et al. A new immunohistochemical marker, insulinoma-associated protein 1 (INSM1), for Merkel cell carcinoma: evaluation of 24 cases. Ann Diagn Pathol 2019; 40:53–58. - PubMed
  18. Ellis DL, Davis RS. Evidence-based management of primary and localized Merkel cell carcinoma: a review. Int J Dermatol 2013; 52:1248–1258. - PubMed
  19. Strub B, Weindel S, Witt P, Grünert J. The interdisciplinary treatment of Merkel cell carcinoma: a retrospective case analysis and review of the current literature. Zentralbl Chir 2009; 134:468–473. - PubMed
  20. Ramahi E, Choi J, Fuller CD, Eng TY. Merkel cell carcinoma. Am J Clin Oncol 2013; 36:299–309. - PubMed
  21. Andruska N, Fischer-Valuck BW, Mahapatra L, Brenneman RJ, Gay HA, Thorstad WL, et al. Association between surgical margins larger than 1 cm and overall survival in patients with Merkel cell carcinoma. JAMA Dermatol 2021; 157:540–548. - PubMed
  22. Tarabadkar ES, Fu T, Lachance K, Hippe DS, Pulliam T, Thomas H, et al. Narrow excision margins are appropriate for Merkel cell carcinoma when combined with adjuvant radiation: analysis of 188 cases of localized disease and proposed management algorithm. J Am Acad Dermatol 2021; 84:340–347. - PubMed
  23. Singh B, Qureshi MM, Truong MT, Sahni D. Demographics and outcomes of stage I and II Merkel cell carcinoma treated with Mohs micrographic surgery compared with wide local excision in the National Cancer Database. J Am Acad Dermatol 2018; 79:126–134.e3. - PubMed
  24. Dokic Y, Nguyen QL, Orengo I. Mohs micrographic surgery: a treatment method for many non-melanocytic skin cancers. Dermatol Online J 2020; 26:13030/qt8zr4f9n4. - PubMed
  25. Poulsen M, Walpole E, Harvey J, Dickie G, O’Brien P, Keller J, et al. Weekly carboplatin reduces toxicity during synchronous chemoradiotherapy for Merkel cell carcinoma of skin. Int J Radiat Oncol Biol Phys 2008; 72:1070–1074. - PubMed
  26. Tai PT, Yu E, Winquist E, Hammond A, Stitt L, Tonita J, Gilchrist J. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 2000; 18:2493–2499. - PubMed
  27. Iyer JG, Blom A, Doumani R, Lewis C, Tarabadkar ES, Anderson A, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med 2016; 5:2294–2301. - PubMed
  28. Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol 2019; 37:693–702. - PubMed
  29. Wilken R, Criscito M, Pavlick AC, Stevenson ML, Carucci JA. Current research in melanoma and aggressive nonmelanoma skin cancer. Facial Plast Surg 2020; 36:200–210. - PubMed
  30. Samimi M. Immune checkpoint inhibitors and beyond: an overview of immune-based therapies in Merkel cell carcinoma. Am J Clin Dermatol 2019; 20:391–407. - PubMed
  31. Choi FD, Kraus CN, Elsensohn AN, Carley SK, Lehmer LM, Nguyen RT, et al. Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: a systematic review. J Am Acad Dermatol 2020; 82:440–459. - PubMed
  32. Hall ET, Fernandez-Lopez E, Silk AW, Dummer R, Bhatia S. Immunologic characteristics of nonmelanoma skin cancers: implications for immunotherapy. Am Soc Clin Oncol Educ Book 2020; 40:1–10. - PubMed
  33. Krieger T, Pearson I, Bell J, Doherty J, Robbins P. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagn Pathol 2020; 15:6. - PubMed
  34. Nakamura M, Magara T, Nojiri Y, Nishihara H, Kato H, Teramoto Y, et al. Increased programmed death ligand-1 expression in metastatic Merkel cell carcinoma associates with better prognosis. J Dermatol Sci 2020; 97:165–167. - PubMed
  35. Bénigni P, Guénolé M, Bonsang B, Marcorelles P, Schick U, Uguen A. Foci of Programmed cell death-ligand 1 (PD-L1)-positive tumor areas with tumor-infiltrating leukocytes (TILs) evocative of a PD-1/PD-L1-related adaptive immune resistance are frequent in Merkel cell carcinoma. Appl Immunohistochem Mol Morphol. 2020; 28:17–22. - PubMed
  36. Saxena A, Rubens M, Ramamoorthy V, Khan H. Risk of second cancers in Merkel cell carcinoma: a meta-analysis of population based cohort studies. J Skin Cancer 2014; 2014:184245. - PubMed
  37. Ishikawa M, Yamamoto T. Malignant melanoma after treatment for Merkel cell carcinoma. An Bras Dermatol 2020; 95:662–664. - PubMed
  38. Chattopadhyay S, Hemminki A, Försti A, Sundquist K, Sundquist J, Hemminki K. Second primary cancers in patients with invasive and in situ squamous cell skin carcinoma, Kaposi sarcoma, and Merkel cell carcinoma: role for immune mechanisms? J Invest Dermatol 2020; 140:48–55.e1. - PubMed
  39. Fang B, Kannan A, Zhao S, Nguyen QH, Ejadi S, Yamamoto M, et al. Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. Sci Rep 2020; 10:8867. - PubMed
  40. Xenou L, Papakonstanti EA. p110δ PI3K as a therapeutic target of solid tumours. Clin Sci (Lond) 2020; 134:1377–1397. - PubMed
  41. Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, et al. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res 2014; 2:27–36. - PubMed
  42. Laniosz V, Onajin O, Sominidi-Damodaran S, Meves A, Gibson LE, Baum CL. Natural killer cell response is a predictor of good outcome in MCPyV+ Merkel cell carcinoma: a case series of 23 patients. J Am Acad Dermatol 2017; 77:31–32. - PubMed
  43. Tabachnick-Cherny S, Pulliam T, Church C, Koelle DM, Nghiem P. Polyomavirus-driven Merkel cell carcinoma: prospects for therapeutic vaccine development. Mol Carcinog 2020; 59:807–821. - PubMed
  44. Czech-Sioli M, Siebels S, Radau S, Zahedi RP, Schmidt C, Dobner T, et al. The Ubiquitin-specific protease Usp7, a novel Merkel cell polyomavirus large T-antigen interaction partner, modulates viral DNA replication. J Virol. 2020; 94:e01638–19. - PubMed
  45. Liu W, Kim GB, Krump NA, Zhou Y, Riley JL, You J. Selective reactivation of STING signaling to target Merkel cell carcinoma. Proc Natl Acad Sci U S A 2020; 117:13730–13739. - PubMed

Publication Types